المؤلفون: Tolaney SM; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Tayob N; Dana-Farber Cancer Institute, Boston, MA., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Massachusetts General Hospital, Boston, MA., Valero V; The University of Texas MD Anderson Cancer Center, Houston, TX., Faggen M; Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Massachusetts General Hospital, Boston, MA., Bose R; Washington University, St Louis, MO., Hu J; Dana-Farber Cancer Institute, Boston, MA., Weckstein D; Dana-Farber Cancer Institute, Boston, MA., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; UNC Chapel Hill, Chapel Hill, NC., Rugo HS; UCSF, San Francisco, CA., Ramaswamy B; OSU Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Washington, Seattle, WA. Currently at University of Illinois at Chicago, Chicago, IL., Constantine M; Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Briccetti F; Dana-Farber Cancer Institute, Boston, MA., Schneider B; IU School of Medicine, Indianapolis, IN., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom K; Duke University, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; The University of Chicago, Chicago, IL., Jankowitz RC; Abramsom Cancer Center, University of Pennsylvania, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu M; Mayo Clinic, Rochester, MN., Ruddy K; Mayo Clinic, Rochester, MN., Zheng Y; Dana-Farber Cancer Institute, Boston, MA., Rosenberg SM; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Gelber RD; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Trippa L; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Barry W; Dana-Farber Cancer Institute, Boston, MA., DeMeo M; Dana-Farber Cancer Institute, Boston, MA., Burstein H; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Partridge A; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Winer EP; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Krop I; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jul 20; Vol. 39 (21), pp. 2375-2385. Date of Electronic Publication: 2021 Jun 02.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Paclitaxel/*therapeutic use , Trastuzumab/*therapeutic use, Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Breast Neoplasms/mortality ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Paclitaxel/pharmacology ; Trastuzumab/pharmacology

المؤلفون: Lynce F; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA.; Georgetown University Medical Center, Washington, DC, USA., Wang H; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA., Pohlmann PR; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA.; Georgetown University Medical Center, Washington, DC, USA., Smaglo B; Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Hwang J; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA., He AR; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA.; Georgetown University Medical Center, Washington, DC, USA., Subramaniam DS; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA.; Georgetown University Medical Center, Washington, DC, USA.; AstraZeneca plc, Gaithersburg, Maryland, USA., Deeken J; Inova Schar Cancer Institute, Inova Health System, Falls Church, Fairfax, VA, USA., Marshall J; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA.; Georgetown University Medical Center, Washington, DC, USA., Pishvaian MJ; Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC, 20007, USA. pishvaim@georgetown.edu.; Georgetown University Medical Center, Washington, DC, USA. pishvaim@georgetown.edu.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Nov; Vol. 84 (5), pp. 1145-1151. Date of Electronic Publication: 2019 Sep 19.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Biomarkers, Tumor/*metabolism , Neoplasms/*drug therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bortezomib/administration & dosage ; Dose-Response Relationship, Drug ; ErbB Receptors/antagonists & inhibitors ; Female ; Humans ; Lapatinib/administration & dosage ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/pathology ; Receptor, ErbB-2/antagonists & inhibitors

المؤلفون: Freedman RA; 1 Dana-Farber Cancer Institute, Boston, MA., Gelman RS; 1 Dana-Farber Cancer Institute, Boston, MA., Anders CK; 2 University of North Carolina at Chapel Hill, Chapel Hill, NC., Melisko ME; 3 University of California at San Francisco, San Francisco, CA., Parsons HA; 1 Dana-Farber Cancer Institute, Boston, MA., Cropp AM; 1 Dana-Farber Cancer Institute, Boston, MA., Silvestri K; 1 Dana-Farber Cancer Institute, Boston, MA., Cotter CM; 1 Dana-Farber Cancer Institute, Boston, MA., Componeschi KP; 1 Dana-Farber Cancer Institute, Boston, MA., Marte JM; 1 Dana-Farber Cancer Institute, Boston, MA., Connolly RM; 4 Johns Hopkins School of Medicine, Baltimore, MD., Moy B; 5 Massachusetts General Hospital, Boston, MA., Van Poznak CH; 6 University of Michigan, Ann Arbor, MI., Blackwell KL; 7 Duke University Medical Center, Durham, NC., Puhalla SL; 8 University of Pittsburgh Cancer Institute, Pittsburgh, PA., Jankowitz RC; 8 University of Pittsburgh Cancer Institute, Pittsburgh, PA., Smith KL; 4 Johns Hopkins School of Medicine, Baltimore, MD., Ibrahim N; 9 The University of Texas MD Anderson Cancer Center, Houston, TX., Moynihan TJ; 10 Mayo Clinic, Rochester, MN., O'Sullivan CC; 10 Mayo Clinic, Rochester, MN., Nangia J; 11 Baylor College of Medicine, Houston, TX., Niravath P; 11 Baylor College of Medicine, Houston, TX., Tung N; 12 Beth Israel Deaconess Medical Center, Boston, MA., Pohlmann PR; 13 Lombardi Comprehensive Cancer Center, Washington, DC., Burns R; 14 The Emmes Corporation, Rockville, MD., Rimawi MF; 11 Baylor College of Medicine, Houston, TX., Krop IE; 1 Dana-Farber Cancer Institute, Boston, MA., Wolff AC; 4 Johns Hopkins School of Medicine, Baltimore, MD., Winer EP; 1 Dana-Farber Cancer Institute, Boston, MA., Lin NU; 1 Dana-Farber Cancer Institute, Boston, MA.

مؤلفون مشاركون: Translational Breast Cancer Research Consortium

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 May 01; Vol. 37 (13), pp. 1081-1089. Date of Electronic Publication: 2019 Mar 12.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Brain Neoplasms/*drug therapy , Brain Neoplasms/*enzymology , Breast Neoplasms/*drug therapy , Breast Neoplasms/*enzymology , Receptor, ErbB-2/*metabolism, Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Cohort Studies ; Female ; Humans ; Middle Aged ; Progression-Free Survival ; Quinolines/administration & dosage ; Quinolines/adverse effects ; Survival Rate

المؤلفون: Adams S; New York University Perlmutter Cancer Center, New York., Diamond JR; University of Colorado Anschutz Medical Campus, Aurora., Hamilton E; Sarah Cannon Research Institute and Tennessee Oncology, Nashville., Pohlmann PR; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Tolaney SM; Dana-Farber Cancer Institute, Boston, Massachusetts., Chang CW; Genentech Inc, South San Francisco, California., Zhang W; Genentech Inc, South San Francisco, California., Iizuka K; Genentech Inc, South San Francisco, California., Foster PG; Genentech Inc, South San Francisco, California., Molinero L; Genentech Inc, South San Francisco, California., Funke R; Genentech Inc, South San Francisco, California., Powderly J; Carolina BioOncology Institute, Huntersville, North Carolina.

المصدر: JAMA oncology [JAMA Oncol] 2019 Mar 01; Vol. 5 (3), pp. 334-342.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Albumins/*administration & dosage , Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Paclitaxel/*administration & dosage , Triple Negative Breast Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Albumins/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease Progression ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Paclitaxel/adverse effects ; Progression-Free Survival ; Time Factors ; Triple Negative Breast Neoplasms/mortality ; Triple Negative Breast Neoplasms/pathology ; United States

المؤلفون: Gao JJ; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD., Tan M; Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC., Pohlmann PR; Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC., Swain SM; Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: Sandra.Swain@georgetown.edu.

المصدر: Clinical breast cancer [Clin Breast Cancer] 2017 Feb; Vol. 17 (1), pp. 76-78. Date of Electronic Publication: 2016 Aug 27.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life*, Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Breast Neoplasms/*drug therapy , Diarrhea/*prevention & control , Proanthocyanidins/*therapeutic use, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Breast Neoplasms/pathology ; Carboplatin/administration & dosage ; Diarrhea/chemically induced ; Diarrhea/epidemiology ; Docetaxel ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Prognosis ; Taxoids/administration & dosage ; Trastuzumab/administration & dosage ; Young Adult

المؤلفون: Falcetta FS; Oncology, Hospital de Clínicas de Porto Alegre, Av. Nilópolis, 125, ap. 303, Porto Alegre, Brazil, 90460-050., Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD

المصدر: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2016 Nov 22; Vol. 11. Cochrane AN: CD005342. Date of Electronic Publication: 2016 Nov 22.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Platinum Compounds/*therapeutic use , Uterine Cervical Neoplasms/*drug therapy, Chemotherapy, Adjuvant/methods ; Cisplatin/administration & dosage ; Female ; Fluorouracil/administration & dosage ; Humans ; Hysterectomy ; Neoplasm Staging ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Survival Analysis ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/radiotherapy ; Uterine Cervical Neoplasms/surgery

المؤلفون: Rosa DD; OncologyUnit,HospitalMoinhos deVento, PortoAlegre,Brazil. dornellesrosa@hotmail.com, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT

المصدر: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2012 Jun 13 (6). Cochrane AN: CD005342. Date of Electronic Publication: 2012 Jun 13.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Platinum Compounds/*therapeutic use , Uterine Cervical Neoplasms/*drug therapy, Chemotherapy, Adjuvant/methods ; Cisplatin/administration & dosage ; Female ; Fluorouracil/administration & dosage ; Humans ; Hysterectomy ; Neoplasm Staging ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/radiotherapy ; Uterine Cervical Neoplasms/surgery

المؤلفون: Rosa DD; Hospital Femina - Grupo Hospitalar Conceicao, Dinarte Ribeiro 212/83, Porto Alegre, Rio Grande do Sul, Brazil, 90570-150., Medeiros LR, Edelweiss MI, Bozzetti MC, Pohlmann PR, Stein AT, Dickinson HO

المصدر: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2009 Jul 08 (3). Cochrane AN: CD005342. Date of Electronic Publication: 2009 Jul 08.

نوع المنشور: Journal Article; Meta-Analysis; Review; Systematic Review

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Platinum Compounds/*therapeutic use , Uterine Cervical Neoplasms/*drug therapy, Chemotherapy, Adjuvant ; Female ; Humans ; Hysterectomy ; Neoplasm Staging ; Radiotherapy, Adjuvant ; Randomized Controlled Trials as Topic ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/radiotherapy ; Uterine Cervical Neoplasms/surgery

المؤلفون: Pohlmann PR, Mernaugh RL, Goff LW

المصدر: The New England journal of medicine [N Engl J Med] 2009 May 14; Vol. 360 (20), pp. 2134; author reply 2135-6.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Colorectal Neoplasms/*drug therapy , Organoplatinum Compounds/*blood, Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Capecitabine ; Cetuximab ; Colorectal Neoplasms/pathology ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Drug Monitoring ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Humans ; Neoplasm Metastasis/drug therapy ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Proto-Oncogene Proteins ; Proto-Oncogene Proteins p21(ras) ; ras Proteins